Frédéric Garban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Frédéric Garban has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Caulier
Translational Research Unit, Section of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway; Faculty of Medicine, Center for Cancer Cell Reprogramming (CanCell), Institute for Clinical Medicine, University of Oslo, Oslo, Norway; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
2 shared publications - Benoît Polack
TIMC Laboratory, CNRS – Grenoble Alpes University, Grenoble, France
2 shared publications - Bertrand Toussaint
CHU Grenoble Alpes, université Grenoble Alpes, TIMC, France
2 shared publications - David Laurin
INSERM U1209, CNRS UMR5309, Institute for Advanced Biosciences, University Grenoble Alpes, F-38000 Grenoble, France
2 shared publications Jacques-Olivier Bay
CHU de Clermont-Ferrand, Clermont-Ferrand, France
2 shared publications- Lionel Berthoin
Univ. Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG UMR 5525, Grenoble F-38041, France
2 shared publications
Latest Publications
- 8 December 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 134, 154-156
High-risk allogeneic stem cells transplantation in advanced age patients with uncontrolled sickle cell disease
- 8 December 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 134, 154-156
High-risk allogeneic stem cells transplantation in advanced age patients with uncontrolled sickle cell disease
- 9 July 2024
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 43 (5) , 101404
Perioperative Patient Blood Management (excluding obstetrics): Guidelines from the French National Authority for Health
- 9 July 2024
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 43 (5) , 101404
Perioperative Patient Blood Management (excluding obstetrics): Guidelines from the French National Authority for Health
- Top Cited PapersOpen Access
- 28 December 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (1)
Severe acute kidney injury related to haemolysis after pulsed field ablation for atrial fibrillation
Pulsed field ablation (PFA) has been proposed as a novel alternative to radiofrequency (RF) and cryoablation in the treatment of atrial fibrillation (AF). Following the occurrence of two cases of acute kidney injury (AKI) secondary to haemolysis after a PFA procedure, we evaluated haemolysis in a cohort of consecutive patients. Two cases of AKI occurred in last May and June 2023. AKI was secondary to acute and severe haemolysis after a PFA procedure. From June 2023, a total of 68 consecutive patients (64.3 ± 10.5 years) undergoing AF ablation with PFA were enrolled in the study. All patients had a blood sample the day after the procedure for the assessment of haemolysis indicators. The pentaspline PFA catheter was used with a total number of median applications of 64 (54; 76). Nineteen patients (28%) showed significantly depleted haptoglobin levels (P = 0.011. More than 70 applications seem to have better sensitivity and specificity to predict haemolysis. Intravascular haemolysis can occur after certain procedures of PFA. Acute kidney injury is a phenomenon that appears to be very rare after a PFA procedure. However, caution must be exercised in the number of applications to avoid severe haemolysis.
- 28 December 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (1)
Top Cited PapersOpen AccessSevere acute kidney injury related to haemolysis after pulsed field ablation for atrial fibrillation
Pulsed field ablation (PFA) has been proposed as a novel alternative to radiofrequency (RF) and cryoablation in the treatment of atrial fibrillation (AF). Following the occurrence of two cases of acute kidney injury (AKI) secondary to haemolysis after a PFA procedure, we evaluated haemolysis in a cohort of consecutive patients. Two cases of AKI occurred in last May and June 2023. AKI was secondary to acute and severe haemolysis after a PFA procedure. From June 2023, a total of 68 consecutive patients (64.3 ± 10.5 years) undergoing AF ablation with PFA were enrolled in the study. All patients had a blood sample the day after the procedure for the assessment of haemolysis indicators. The pentaspline PFA catheter was used with a total number of median applications of 64 (54; 76). Nineteen patients (28%) showed significantly depleted haptoglobin levels (P = 0.011. More than 70 applications seem to have better sensitivity and specificity to predict haemolysis. Intravascular haemolysis can occur after certain procedures of PFA. Acute kidney injury is a phenomenon that appears to be very rare after a PFA procedure. However, caution must be exercised in the number of applications to avoid severe haemolysis.
- 14 February 2023
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 58 (5) , 594-596
Outcome of haematopoietic cell transplantation in children with lysosomal acid lipase deficiency: a study on behalf of the EBMT Inborn Errors Working Party
- 14 February 2023
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 58 (5) , 594-596
Outcome of haematopoietic cell transplantation in children with lysosomal acid lipase deficiency: a study on behalf of the EBMT Inborn Errors Working Party
- 12 January 2022
- Published by Wiley in Transfusion Medicine
- Vol. 32 (2) , 175-177
The impact of pathogen‐reduced platelets in acute leukaemia treatment on the total blood product requirement: a subgroup analysis of an EFFIPAP randomised trial
Objective: To evaluate the impact of pathogen‐reduced (PR) platelet transfusions on blood products requirement for clinical practice.Background: PR platelets are increasing in use as standard blood products. However, few randomised trials have evaluated their impact on bleeding control or prevention. Furthermore, PR platelets recirculate less than untreated platelets.Methods: A subgroup study of the randomised clinical trial EFFIPAP compared three arms of platelet preparations (PR: P‐PRP/PAS, additive solution: P‐PAS and plasma P‐P arms respectively). The subgroup of acute leukaemia patients, in their chemotherapy induction phase, included 392 patients (133 P‐PRP/PAS arm, 132 P‐PAS arm and 130 P‐P arm). Blood requirements were analysed across over periods of 7 days.Results: The number of platelet transfusions per week was significantly higher in the P‐PRP/PAS group 2.3 [1.6–3.3] compared to the control groups 1.9 [1.3–2.8] and 2.0 [1.3–3.0] for P‐P and P‐PAS groups respectively (p < 0.0001). However, the total number of platelets transfused per week was not different. The number of red blood cell concentrates (RBC) transfusion per week did not differ either.Conclusion: In a homogeneous group of patients, platelet pathogen reduction resulted in an increased number of platelet units transfused per week while having no impact on the total number of platelets transfused or the number of RBC transfusion; resulting to an average requirement of 2 RBC and 2–3 platelets transfusions per week of marrow aplasia.
- 12 January 2022
- Published by Wiley in Transfusion Medicine
- Vol. 32 (2) , 175-177
The impact of pathogen‐reduced platelets in acute leukaemia treatment on the total blood product requirement: a subgroup analysis of an EFFIPAP randomised trial
Objective: To evaluate the impact of pathogen‐reduced (PR) platelet transfusions on blood products requirement for clinical practice.Background: PR platelets are increasing in use as standard blood products. However, few randomised trials have evaluated their impact on bleeding control or prevention. Furthermore, PR platelets recirculate less than untreated platelets.Methods: A subgroup study of the randomised clinical trial EFFIPAP compared three arms of platelet preparations (PR: P‐PRP/PAS, additive solution: P‐PAS and plasma P‐P arms respectively). The subgroup of acute leukaemia patients, in their chemotherapy induction phase, included 392 patients (133 P‐PRP/PAS arm, 132 P‐PAS arm and 130 P‐P arm). Blood requirements were analysed across over periods of 7 days.Results: The number of platelet transfusions per week was significantly higher in the P‐PRP/PAS group 2.3 [1.6–3.3] compared to the control groups 1.9 [1.3–2.8] and 2.0 [1.3–3.0] for P‐P and P‐PAS groups respectively (p < 0.0001). However, the total number of platelets transfused per week was not different. The number of red blood cell concentrates (RBC) transfusion per week did not differ either.Conclusion: In a homogeneous group of patients, platelet pathogen reduction resulted in an increased number of platelet units transfused per week while having no impact on the total number of platelets transfused or the number of RBC transfusion; resulting to an average requirement of 2 RBC and 2–3 platelets transfusions per week of marrow aplasia.
- 29 October 2019
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (4) , 749-757
Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor
Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy for acute myeloid leukemia. In the absence of an HLA-matched related or unrelated donor (MRD or MUD), the best alternative donor source remains controversial. Umbilical cord blood and haploidentical donors offer a shorter delay from indication to transplantation. This retrospective multicentre study of a French registry compares overall survival in the 18 months following registration in the absence of a MRD between four types of donors. Between 2012 and 2016, 1302 patients were transplanted using MUD (control, n = 803), mismatched MUD (n = 219), umbilical cord blood (n = 153) and haploidentical (n = 127) donors. Multivariate analyses were conducted for overall survival after registration, after transplant, and transplant-related mortality. After adjustment for variables, the type of donor did not influence any of the three end points. Our results confirmed the significant negative impact of longer time between registration and transplant: HR = 1.04 [1.02–1.06] (p < 0.0001). This indicates a positive correlation between better survival and shorter registration-to-transplantation wait time. In the absence of a sibling donor, the alternative stem cell source does not impact early survival in acute myeloid leukemia patients. The minimization of registration-to-transplantation time should be considered when weighing the alternative donor options.
- 29 October 2019
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (4) , 749-757
Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor
Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy for acute myeloid leukemia. In the absence of an HLA-matched related or unrelated donor (MRD or MUD), the best alternative donor source remains controversial. Umbilical cord blood and haploidentical donors offer a shorter delay from indication to transplantation. This retrospective multicentre study of a French registry compares overall survival in the 18 months following registration in the absence of a MRD between four types of donors. Between 2012 and 2016, 1302 patients were transplanted using MUD (control, n = 803), mismatched MUD (n = 219), umbilical cord blood (n = 153) and haploidentical (n = 127) donors. Multivariate analyses were conducted for overall survival after registration, after transplant, and transplant-related mortality. After adjustment for variables, the type of donor did not influence any of the three end points. Our results confirmed the significant negative impact of longer time between registration and transplant: HR = 1.04 [1.02–1.06] (p < 0.0001). This indicates a positive correlation between better survival and shorter registration-to-transplantation wait time. In the absence of a sibling donor, the alternative stem cell source does not impact early survival in acute myeloid leukemia patients. The minimization of registration-to-transplantation time should be considered when weighing the alternative donor options.
- Open Access
- 1 April 2018
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 4 (4) , 468-475
Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases
Platelet transfusion to prevent or treat bleeding due to thrombocytopenia is standard therapy worldwide.1 In recent years, the risk of transfusion-transmitted infections (TTIs) has been greatly reduced.2 However, infectious agent transmission—in particular, bacteria—remains a significant risk associated with platelet transfusion.3-5 One solution to further reduce the risk of TTIs is photochemical pathogen reduction (PR),6 a process by which pathogens are significantly depleted in number,7 albeit with some exceptions.8,9 However, PR technologies, such as amotosalen–UV-A treatment, induce functional platelet alterations.10,11 Previous clinical studies12,13 have raised concerns about the clinical effectiveness of pathogen-reduced platelets compared with standard untreated platelets. A 2013 Cochrane meta-analysis14 of published clinical trials reported a nonstatistically significant relative risk of 1.06 (95% CI, 0.93-1.21; P = .39) with regard to grade 2 or higher bleeding associated with pathogen-reduced platelets and concluded that not enough evidence was available to be sure that such platelets work as effectively as standard platelets to prevent bleeding. A recently updated analysis15 reported a 1.10 (95% CI, 0.97-1.25; P = .15) relative risk of grade 2 or higher bleeding associated with pathogen-reduced platelets.
- 1 April 2018
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 4 (4) , 468-475
Open AccessComparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases
Platelet transfusion to prevent or treat bleeding due to thrombocytopenia is standard therapy worldwide.1 In recent years, the risk of transfusion-transmitted infections (TTIs) has been greatly reduced.2 However, infectious agent transmission—in particular, bacteria—remains a significant risk associated with platelet transfusion.3-5 One solution to further reduce the risk of TTIs is photochemical pathogen reduction (PR),6 a process by which pathogens are significantly depleted in number,7 albeit with some exceptions.8,9 However, PR technologies, such as amotosalen–UV-A treatment, induce functional platelet alterations.10,11 Previous clinical studies12,13 have raised concerns about the clinical effectiveness of pathogen-reduced platelets compared with standard untreated platelets. A 2013 Cochrane meta-analysis14 of published clinical trials reported a nonstatistically significant relative risk of 1.06 (95% CI, 0.93-1.21; P = .39) with regard to grade 2 or higher bleeding associated with pathogen-reduced platelets and concluded that not enough evidence was available to be sure that such platelets work as effectively as standard platelets to prevent bleeding. A recently updated analysis15 reported a 1.10 (95% CI, 0.97-1.25; P = .15) relative risk of grade 2 or higher bleeding associated with pathogen-reduced platelets.
- 1 August 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 529 (1-2) , 65-74
Targeted release of transcription factors for human cell reprogramming by ZEBRA cell-penetrating peptide
- 1 August 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 529 (1-2) , 65-74
Targeted release of transcription factors for human cell reprogramming by ZEBRA cell-penetrating peptide
- 1 November 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 513 (1-2) , 678-687
Targeted release of transcription factors for cell reprogramming by a natural micro-syringe
- 1 November 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 513 (1-2) , 678-687
Targeted release of transcription factors for cell reprogramming by a natural micro-syringe
- Open Access
- 1 September 2014
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 20 (9) , 1451-1454
Alemtuzumab for Severe Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease
- 1 September 2014
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 20 (9) , 1451-1454
Open AccessAlemtuzumab for Severe Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease